| Sign In to gain access to subscriptions and/or personal tools. |
Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot studyHarry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
Harry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Harry R. Horvitz Chair in Palliative Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
Harry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Palliative Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
Harry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
Harry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
Harry R. Horvitz Center for Palliative Medicine, a World Health Organization Demonstration Project in Palliative Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio Psychostimulants such as methylphenidate are used for fatigue in cancer patients. We report a prospective, open-label, pilot study of the successful use of methylphenidate to treat fatigue in nine of 11 consecutive patients with advanced cancer. Seven had received radiation or chemotherapy, a median of three weeks (range from one to 30 weeks) prior to methylphenidate. A rapid onset of benefit was noted, even in the presence of mild anemia. Sedation and pain also improved in some. Only one patient had side effects severe enough to stop the medication.
Key Words: cancer fatigue methylphenidate psychostimulant symptom management
American Journal of Hospice and Palliative Medicine®, Vol. 18, No. 3,
187-192 (2001) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||






